Gastroesophageal Junction research hub
5 indexed studies · 5 currently recruiting
- recruitingPHASE1, PHASE2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
This study looks at new drug combinations with a medicine called pembrolizumab and chemotherapy for advanced stomach or oesophageal cancer that can't be removed by surgery. It's in early stages (Phase 1/2) and aims to find safe doses and see how well the treatments work.
United States · Brazil · Chile - recruitingPHASE1, PHASE2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
This study looks at new treatments for advanced stomach or gullet cancer that has already been treated once. It compares different drug combinations to see how safe and effective they are for patients whose cancer has come back or spread.
United States · Brazil · Chile - recruitingPHASE1, PHASE2
HTL0039732 in Participants With Advanced Solid Tumours
This study is testing a new drug, HTL0039732, alone and with another cancer medicine, atezolizumab. It's for people with advanced solid tumours, aiming to see if blocking certain signals can help the immune system fight cancer. The goal is to find the right dose and see how well it works.
United Kingdom - recruiting
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
This study, called METABREC, looks back at medical records of people who had surgery for gullet cancer. It aims to understand how often cancer spreads to the brain after surgery and what might increase this risk.
United States · Belgium · France - recruitingPHASE1, PHASE2
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
This study is testing a new drug, UCB4594, for advanced cancers. It's the first time it’s being used in people. Researchers want to find the safest dose, understand side effects, and see if it can shrink certain tumours by helping the body's immune system.
United Kingdom